METHODS AND APPARATUS FOR DETECTING AND REACTING TO INSUFFICIENT HYPOGLYCEMIA RESPONSE
A system includes one or more processors and one or more processor-readable storage media storing instructions which, when executed by the one or more processors, cause performance of obtaining an insulin-on-board (IOB) value, wherein the IOB value is a quantity of insulin remaining in a patient following delivery of a bolus of insulin, scaling a total daily dose (TDD) value by a factor, to generate a result having a value that is less than the TDD value, based on determining that the IOB value is greater than the result, identifying a condition in which the patient's glucose level will continue to decrease after suspension of basal insulin dosage delivery, and responsive to identifying the condition, causing performance of an action for preventing the patient's glucose level from falling into a hypoglycemic range in combination with the suspension of basal insulin dosage delivery.
1 . A processor-implemented method comprising:
obtaining, by a controller associated with an insulin delivery pump, an amount of insulin remaining in a body of a patient;
obtaining, by the controller, a quantity of insulin needed by the patient within a future time period;
based on determining that the amount of insulin remaining in the body is greater than the quantity of insulin needed by the patient within the future time period, identifying, by the controller, a condition in which the patient's glucose level will continue to decrease during the future time period despite suspension of basal insulin dosage delivery; and
responsive to identifying the condition, causing, by the controller, performance of an action for preventing the patient's glucose level from falling into a hypoglycemic range in combination with the suspension of basal insulin dosage delivery.
2 . The method of claim 1 , further comprising:
prior to identifying the condition, causing a medication delivery device to suspend the basal insulin dosage delivery based on identifying a glucose trend in the patient toward the hypoglycemic range.
3 . The method of claim 2 , wherein identifying the glucose trend in the patient comprises:
obtaining a plurality of glucose values;
calculating a glucose trend value based on computing a derivative of the plurality of glucose values; and
comparing the glucose trend value to a hypoglycemia threshold.
4 . The method of claim 1 , wherein causing the action comprises communicating a command to a medication delivery device.
5 . The method of claim 1 , wherein the action comprises delivering glucagon to the patient.
6 . The method of claim 1 , wherein the action comprises presenting a recommendation to ingest a substance for increasing the patient's glucose level.
7 . A processor-implemented method comprising:
determining, by a controller associated with an insulin delivery pump, that an amount of insulin remaining in a body of a patient is greater than a quantity of insulin needed by the patient within a future time period;
based on determining that the amount of insulin remaining in the body is greater than the quantity of insulin needed by the patient within the future time period, identifying, by the controller, a condition in which the patient's glucose level will continue to decrease during the future time period despite suspension of basal insulin dosage delivery; and
responsive to identifying the condition, causing, by the controller, performance of an action for preventing the patient's glucose level from falling into a hypoglycemic range in combination with the suspension of basal insulin dosage delivery.
8 . The method of claim 7 , further comprising:
prior to identifying the condition, causing a medication delivery device to suspend the basal insulin dosage delivery based on identifying a glucose trend in the patient toward the hypoglycemic range.
9 . The method of claim 8 , wherein identifying the glucose trend in the patient comprises:
obtaining a plurality of glucose values;
calculating a glucose trend value based on computing a derivative of the plurality of glucose values; and
comparing the glucose trend value to a hypoglycemia threshold.
10 . The method of claim 7 , wherein causing the action comprises communicating a command to a medication delivery device.
11 . The method of claim 7 , wherein the action comprises delivering glucagon to the patient.
12 . The method of claim 7 , wherein the action comprises presenting a recommendation to ingest a substance for increasing the patient's glucose level.
13 . A processor-implemented method comprising:
in response to a suspension of continuous basal insulin delivery by an insulin delivery pump, predicting, by a controller associated with the insulin delivery pump, a condition indicating continuing hypoglycemia despite suspension of basal insulin dosage delivery based at least in part on an amount of insulin remaining in a body of a patient; and
responsive to identifying the condition, causing, by the controller, performance of an action.
14 . The method of claim 13 , wherein causing performance of the action comprises communicating a command to a medication delivery device.
15 . The method of claim 13 , wherein the action comprises delivering glucagon to the patient.
16 . The method of claim 13 , wherein the action comprises presenting a recommendation to ingest a substance for increasing the patient's glucose level.
17 . The method of claim 13 , wherein the action comprises presenting at least one of: an audio alert or a visual alert.
18 . The method of claim 13 , wherein the performance of the action is provided prior to occurrence of the condition indicating continuing hypoglycemia.
19 . The method of claim 13 , further comprising determining that a rate of change of glucose levels of a patient exceeds a change threshold, wherein suspension of the continuous basal insulin delivery is responsive to determining that the rate of change of the glucose levels of the patient exceeds the change threshold.
20 . The method of claim 13 , wherein predicting the condition indicating continuing hypoglycemia comprises determining that the amount of insulin remaining in the body of the patient is greater than a quantity of insulin required by the patient.